Patients diagnosed with basal-like breast cancer face a more aggressive disease course and more dismal prognosis than patients diagnosed with luminal A and luminal B breast cancer molecular subtypes (1-4). We mined published microarray data (5, 6) to understand in an unbiased fashion the most distinguishing transcriptional features of tumors from patients with basal or basal-like subtype breast cancer. We observed transcriptome-wide differential expression of protein phosphatase 2 regulatory

more »

... unit B"alpha, PPP2R3A, when comparing tumors of patients with basal-like breast cancer with that of other PAM50 molecular subtypes. PPP2R3A mRNA was present at significantly higher quantities in the tumors of patients with basal-like breast cancer. Analysis of patient survival data revealed that PPP2R3A primary tumor expression was correlated with distant metastasis-free survival in HER2+ subtype breast cancer. Elevated PPP2R3A expression appears to distinguish basal-like human breast cancer from the other molecular subtypes.